Epilepsy Foundation's 2014 Pipeline Conference to Showcase Innovation and Advancements in the Treatment of Seizures
Conference Unites Innovators, Clinicians, Industry, Investors and the Epilepsy Community in San Francisco on June 5-7, 2014
Registration Now Open
LANDOVER, Md., Jan. 16, 2014 /PRNewswire-USNewswire/ -- The Epilepsy Foundation announced today that the 4th Biennial Epilepsy Pipeline Update Conference 2014, an initiative of the Epilepsy Therapy Project, will be held on June 5-7, 2014 at the Hyatt Regency San Francisco. Showcasing the most promising epilepsy therapies from healthcare companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy and seizures, this year's conference will feature the third annual "Shark Tank" competition, in addition to a day designated for people with epilepsy, families and advocates. Registration for the conference is now open.
The Epilepsy Pipeline Update Conference brings together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation and product development. Speakers and attendees will include emerging biotech and medical technology companies, major pharmaceutical and device companies, and researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances. Presenting companies and organizations selected to speak on their clinical programs and products were hand-chosen by the Epilepsy Foundation's prestigious Scientific and Business Advisory Boards.
This year's program will also include panel discussions on topics such as the role of collaboration between small and large companies, how to get products in need of funding to the marketplace, who is funding epilepsy and CNS innovation today, and how the NIH facilitates early stage drug development.
"The Epilepsy Foundation's Pipeline Conference is recognized as the premier business and scientific forum for driving innovation in the field of epilepsy and neurology," said Philip M. Gattone, President and CEO of the Epilepsy Foundation. "Each year, this conference brings together great minds in R&D, clinical thought leaders, investors and industry leaders who are focused on accelerating epilepsy drug and device development."
"This conference has grown to attract an impressive audience. Companies are recognizing the need for and promise in developing potential new therapeutics for epilepsy," said Jacqueline French, MD, Professor in the Department of Neurology, Comprehensive Epilepsy Center, New York University. "I look forward to the opportunity to be updated on the latest innovations in the pipeline with the potential to ultimately benefit the epilepsy community."
The "Shark Tank" competition, which will be held on the second day of the conference, is designed to spur breakthroughs that will change the lives of people living with epilepsy and seizures. Over the past two years, entrepreneurs, scientists, clinicians, industrial design engineers and members of the epilepsy community have been recognized for their truly inventive product concepts, which have ranged from promising new therapeutics or technologies to new products that improve the quality-of-life for people living with epilepsy.
This year's winner will be selected during the Epilepsy Pipeline Conference by live audience vote from the epilepsy community and a panel of distinguished reviewers. The Shark Tank award recipient will receive international recognition and a cash prize to fund the development of his or her novel idea. Chosen finalists will compete for grants totaling $200,000 to support the development of important new products, technologies or therapeutic concepts. Additional details on how to enter the contest will be announced shortly.
The third day of the conference, Saturday, June 7, 2014, will feature a family day with free registration, dedicated to people with epilepsy, their friends, families and advocates. The program will feature topics such as the current state of epilepsy research and what's in the pipeline, dietary therapies and wellness, devices to treat epilepsy and advances in surgery. The subject of medical marijuana will also be explored.
Pharmaceutical and biotechnology industry executives, investors, clinical scientists, technology transfer executives and members of the epilepsy community are invited to attend this comprehensive forum. To register for the Epilepsy Pipeline Update Conference 2014 or obtain additional program information, please visit http://my.epilepsy.com/etp/pipeline2014/program.
When a person has two or more unprovoked seizures, they have epilepsy, which affects more than 2 million people in the United States and 65 million people worldwide. This year, another 150,000 people in our country will be diagnosed with epilepsy. Despite all available treatments, four out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control.
About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with 47 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and sudden unexpected death in epilepsy (SUDEP), find a cure and overcome the challenges created by epilepsy through efforts including education, advocacy and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com.
SOURCE Epilepsy Foundation